2007
DOI: 10.1016/j.athoracsur.2007.03.099
|View full text |Cite
|
Sign up to set email alerts
|

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

12
109
0
3

Year Published

2009
2009
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 130 publications
(124 citation statements)
references
References 30 publications
12
109
0
3
Order By: Relevance
“…2,3 There is presently no available data indicating the optimal management of patients with advanced disease. In particular, the role of chemotherapy remains unclear and these patients are often treated according to the results of trials having enrolled patients with lung squamous cell carcinoma or adenocarcinoma.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…2,3 There is presently no available data indicating the optimal management of patients with advanced disease. In particular, the role of chemotherapy remains unclear and these patients are often treated according to the results of trials having enrolled patients with lung squamous cell carcinoma or adenocarcinoma.…”
Section: Discussionmentioning
confidence: 99%
“…1 Indeed, recent studies focusing on the clinical outcome of SC have reported significantly worse survival and higher recurrence rates in comparison with patients with other histological subtypes of NSCLC. 2,3 During the last few years, significant advances in the development of new molecularly targeted agents have been made in the field of NSCLC. These agents aim to inhibit specific pathways and key molecules involved in tumor growth and progression.…”
mentioning
confidence: 99%
“…[11][12][13][14] Although the molecular characteristics of the more common subtypes of lung carcinoma have been extensively studied, the molecular features and presence of targetable genetic abnormalities in pulmonary sarcomatoid carcinoma are largely unknown. The currently available chemotherapy for sarcomatoid carcinoma is highly ineffective, [4][5][6][7] and thus targeted therapy is a very attractive therapeutic option to improve outcome. A recent study reported frequent MET exon 14 skipping mutations in pulmonary sarcomatoid carcinomas, which may be targetable, in addition to mutations in other genes without currently available targeted therapy, including TP53 and KRAS.…”
mentioning
confidence: 99%
“…[1][2][3][4][5][6][7] The poorly differentiated nature is reflected by the presence of at least 10% tumor giant cells or spindle-shaped cells, hence the designation as 'sarcomatoid'. The sarcomatoid areas may be observed as a form of progression of other types of lung carcinoma, or the entire tumor may be composed of sarcomatoid morphology.…”
mentioning
confidence: 99%
“…On the whole, patients with PSCs have poorer overall survival compared with patients with conventional NSCLCs [Martin et al 2007;Mochizuki et al 2008;Rossi et al 2003;Chang et al 2001]. In one study of resected pulmonary lesions, 63 PSC patients were matched 1:1 with NSCLC patients.…”
Section: Discussionmentioning
confidence: 99%